Prophylactic Use of an Implantable Cardioverter–Defibrillator after Acute Myocardial Infarction
Stefan H. Hohnloser(Goethe University Frankfurt), Stuart J. Connolly(Population Health Research Institute), Paul Dorian(St. Michael's Hospital), Robin S. Roberts(Impact), Eric Fain(St. Jude Medical Center), Michael Gent(University of Aberdeen), John Hampton(Nottingham General Hospital), Karl Heinz Kuck(Asklepios Klinik St. Georg), Róbert Hatala
Cited by 1,519
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
|Heart Rhythm|2017|2.7k
Subclinical Atrial Fibrillation and the Risk of Stroke
|New England Journal of Medicine|2012|2.1k
Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
|New England Journal of Medicine|2010|1.8k
Canadian Implantable Defibrillator Study (CIDS)
|Circulation|2000|1.6k